Pegvisomant

Drug Levels and Effects:




Summary of Use during Lactation:


Limited data indicate that pegvisomant is poorly excreted into breastmilk. Because pegvisomant is not orally absorbed, it is unlikely to adversely affect the breastfed infant.


Drug Levels:


A woman was being treated during pregnancy for acromegaly with subcutaneous pegvisomant at a dosage that was progressively escalated from 15 mg to 25 mg daily during the course of pregnancy, and presumably postpartum. At an unreported time postpartum, pegvisomant was not detectable (<50 mcg/L) in breastmilk. The patient's breastmilk growth hormone concentration was 0.6 mcg/L compared to <0.1 mcg/l="" in="" 3="" breastmilk="" samples="" from="" normal="" healthy="">

Infant Levels.

Relevant published information was not found as of the revision date.


Effects in Breastfed Infants:


Relevant published information was not found as of the revision date.


Possible Effects on Lactation:


Relevant published information was not found as of the revision date.


References:


1. Brian SR, Bidlingmaier M, Wajnrajch MP et al. Treatment of acromegaly with pegvisomant during pregnancy: maternal and fetal effects. J Clin Endocrinol Metab. 2007; 92 :3374-7. PMID:17595256



Substance Identification:




Substance Name:

Pegvisomant

CAS Registry Number:

218620-50-9

Drug Class:


  • Human Growth Hormone Analogues and Derivatives

  • Growth Hormone Receptor Antagonists


  • Administrative Information:




    LactMed Record Number:


    607


    Last Revision Date:


    Disclaimer:Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.